Wang Y, Xie Y, Hu S, Ai W, Tao Y, Tang H et al. Systematic Review and Meta-Analyses of The Interaction Between HIV Infection And COVID-19: Two Years’ Evidence Summary[J]. Front Immunol 2022,13:864838. https://doi.org/10.3389/fimmu.2022.864838.

Wu M, Ming F, Wu S, Liu Y, Zhang X, Guo W et al. Risk of SARS-CoV-2 infection among people living with HIV in Wuhan, China[J]. Front Public Health 2022,10:833783. https://doi.org/10.3389/fpubh.2022.833783.

D’Souza G, Springer G, Gustafson D, Kassaye S, Alcaide ML, Ramirez C, et al. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study[J]. HIV Res Clin Pract. 2020;21(5):130–9. https://doi.org/10.1080/25787489.2020.1844521.

Article  PubMed  CAS  Google Scholar 

Kanwugu ON, Adadi P. HIV/SARS-CoV-2 co-infection: a global perspective[J]. J Med Virol 2021,93(2):726–32. https://doi.org/10.1002/jmv.26321.

He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: characteristics and prevention[J]. MedComm (2020),2021,2(4):838–45. https://doi.org/10.1002/mco2.110.

Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet 2022,399(10323):437–46. https://doi.org/10.1016/S0140-6736(22)00017-4.

Mseka UL, Mandolo J, Nyoni K, Divala O, Kambalame D, Mapemba D et al. Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi[J]. EClinicalMedicine,2023,56:101800. https://doi.org/10.1016/j.eclinm.2022.101800.

Zhang H, Chen W, Ye X, Zhou Y, Zheng Y, Weng Z et al. Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and omicron variant strain in Quanzhou: a real–world study[J]. Exp Ther Med 2023,25(1):62. https://doi.org/10.3892/etm.2022.11761.

Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT. Estimating the transmission dynamics of SARS-CoV-2 omicron BF.7 in Beijing after the adjustment of zero-COVID policy in November - December 2022[J]. Nat Med,2023. https://doi.org/10.1038/s41591-023-02212-y.

Tan Y, Zou S, Ming F, Zhang Z, Xing Z, Wu S et al. Early Efficacy and Safety of the third dose inactivated COVID-19 vaccine among people living with HIV[J]. J Acquir Immune Defic Syndr 2022,90(3):e1–3. https://doi.org/10.1097/QAI.0000000000002953.

Zou S, Guo W, Wu S, Ming F, Tan Y, Wu M et al. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV[J]. Front Immunol 2022,13:988304. https://doi.org/10.3389/fimmu.2022.988304.

Zou S, Wu M, Ming F, Wu S, Guo W, Marley G et al. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals[J]. AIDS Res Ther 2022,19(1):33. https://doi.org/10.1186/s12981-022-00459-y.

Wu S, Zhang Y, Ming F, Zou S, Wu M, Guo W et al. Adverse events of inactivated COVID-19 vaccine in HIV-infected adults[J]. AIDS Res Ther 2021,18(1):92. https://doi.org/10.1186/s12981-021-00416-1.

Tarcsai KR, Corolciuc O, Tordai A, Ongrádi J. SARS-CoV-2 infection in PLWH: potential role in the high mutational load of the Omicron variant emerging in South Africa[J]. Geroscience,2022:1–9. https://doi.org/10.1007/s11357-022-00603-6.

Gagliardini R, Vergori A, Lorenzini P, Cicalini S, Pinnetti C, Mazzotta V et al. Characteristics and outcomes of COVID-19-Related hospitalization among PLWH[J]. J Clin Med 2022,11(6). https://doi.org/10.3390/jcm11061546.

SeyedAlinaghi S, Karimi A, MohsseniPour M, Barzegary A, Mirghaderi SP, Fakhfouri A et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence[J]. Immun Inflamm Dis 2021,9(4):1160–85. https://doi.org/10.1002/iid3.497.

Fajgenbaum DC, June CH. Cytokine Storm[J]. N Engl J Med. 2020;383(23):2255–73. https://doi.org/10.1056/NEJMra2026131.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B et al. Sharing CD4 + T cell loss: when COVID-19 and HIV collide on Immune System[J]. Front Immunol 2020,11:596631. https://doi.org/10.3389/fimmu.2020.596631.

Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China[J]. J Med Virol 2020,92(6):529–30. https://doi.org/10.1002/jmv.25732.

Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis[J]. Am J Transpl 2020,20(7):1947–8. https://doi.org/10.1111/ajt.15905.

Mascolo S, Romanelli A, Carleo MA, Esposito V. Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better[J]. J Med Virol 2020,92(10):1777–8. https://doi.org/10.1002/jmv.25881.

Guo W, Ming F, Feng Y, Zhang Q, Mo P, Liu L et al. Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China[J]. J Int AIDS Soc 2020,23(7):e25568. https://doi.org/10.1002/jia2.25568.

Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B, et al. Sharing CD4 + T cell loss: when COVID-19 and HIV collide on Immune System. Front Immunol. 2020;11:596631. https://doi.org/10.3389/fimmu.2020.596631.

Article  PubMed  PubMed Central  CAS  Google Scholar 

SeyedAlinaghi S, Karimi A, MohsseniPour M, Barzegary A, Mirghaderi SP, Fakhfouri A, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021;9(4):1160–85. https://doi.org/10.1002/iid3.497.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, comorbidities, and outcomes in a Multicenter Registry of patients with Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021;73(7):e1964–72. https://doi.org/10.1093/cid/ciaa1339.

Article  PubMed  CAS  Google Scholar 

Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV/AIDS Rep. 2022;19(5):425–32. https://doi.org/10.1007/s11904-022-00618-w.

Article  PubMed  PubMed Central  Google Scholar 

Patel VV, Felsen UR, Fisher M, Fazzari MJ, Ginsberg MS, Beil R et al. Clinical outcomes and inflammatory markers by HIV Serostatus and viral suppression in a large cohort of patients hospitalized with COVID-19[J]. J Acquir Immune Defic Syndr 2021,86(2):224–30. https://doi.org/10.1097/QAI.0000000000002578.

Tan Y, Zou S, Ming F, Wu S, Guo W, Wu M, et al. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines. Front Immunol. 2023;14:1174379. https://doi.org/10.3389/fimmu.2023.1174379.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants[J]. Nat 2022,603(7903):919–25. https://doi.org/10.1038/s41586-022-04466-x.

Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study[J]. Lancet 2022,399(10324):521–9. https://doi.org/10.1016/S0140-6736(22)00094-0.

Yan Y, Davgadorj C, Lyu C, Zhang S, Qiu Y. Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study[J]. J Infect,2022,85(4): e109–11. https://doi.org/10.1016/j.jinf.2022.06.032.

Varshney K, Ghosh P, Stiles H, Iriowen R. Risk factors for COVID-19 mortality among people living with HIV: a scoping Review[J]. AIDS Behav. 2022;26(7):2256–65. https://doi.org/10.1007/s10461-022-03578-9.

Article  PubMed  PubMed Central  Google Scholar 

Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform[J]. Lancet HIV 2021, 8(1):e24–32. https://doi.org/10.1016/S2352-3018(20)30305-2.

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with COVID-19-related death using OpenSAFELY[J]. Nat 2020,584 (7821):430–6. https://doi.org/10.1038/s41586-020-2521-4.

Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J et al. Sex differences in immune responses that underlie COVID-19 disease outcomes[J]. Nat 2020,588(7837):315–20. https://doi.org/10.1038/s41586-020-2700-3.

Souyris M, Cenac C, Azar P, Daviaud D, Canivet A, Grunenwald S et al. TLR7 escapes X chromosome inactivation in immune cells[J]. Sci Immunol,2018,3(19):eaap8855. https://doi.org/10.1126/sciimmunol.aap8855.

Overton ET, Weir IR, Zanni MV, Fischinger S, MacArthur RD, Aberg JA et al. Asymptomatic SARS-CoV-2 infection is common among ART-Treated people with HIV[J]. J Acquir Immune Defic Syndr 2022,90(4):377–81. https://doi.org/10.1097/QAI.0000000000003000.